Sonali Smith
Hematology & Oncology · Chicago, ILNPI 1215153226
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $33,273 of the $35,233 with a category attached, or 94.4%. 14 manufacturers reported payments, led by Bristol Myers Squibb at 26.1% of the total.
Across 28 payments — averaging $1258.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$9K
- Regeneron$6K
- Genentech, Inc.$5K
- Gilead$3K
- Genmab U.S., Inc.$3K
- Janssen Global Services, LLC$3K
- plus $7K from 8 others
Across 218 payments — averaging $7174.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Portola Pharmaceuticals, LLC$524K
- Bristol Myers Squibb$330K
- Epizyme, Inc.$166K
- Pfizer$150K
- Acerta Pharma LLC$110K
- Seagen Inc.$71K
- plus $213K from 7 others
What the payments were for
- Consulting fees$33,27394%
- Speaking & faculty fees$1,4884%
- Food & beverage$4361%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 7 | $9,186 |
| Regeneron | 5 | $5,562 |
| Genentech, Inc. | 2 | $4,986 |
| Gilead | 1 | $2,850 |
| Genmab U.S., Inc. | 2 | $2,777 |
| Janssen Global Services, LLC | 3 | $2,525 |
| Incyte Corporation | 1 | $1,845 |
| Karyopharm Therapeutics Inc. | 1 | $1,488 |
| Bayer | 1 | $1,400 |
| F. Hoffmann-la Roche AG | 1 | $1,320 |
| Adaptive Biotechnologies Corporation | 1 | $1,200 |
| AbbVie | 1 | $58 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Acrotech Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,233 in reported general payments places this provider in the 85th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 80 | $1,062,988 |
| CalquenceAcalabrutinib Maleate | 41 | $565,984 |
| JaypircaPirtobrutinib | 22 | $440,365 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 11 | $64,854 |
| Acyclovir | 65 | $1,223 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 25 | $64 |
| Prednisone | 17 | $35 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Chicago
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Chih-Yi LiaoChicago$317K
- Rita NandaChicago$286K
- Shuo MaChicago$280K
- Santosh SarafChicago$275K
- Peter RiedellChicago$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.